Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Reduction of linezolid-associated thrombocytopenia by the dose adjustment based on the risk factors such as basal platelet count and body weight.

Niwa T, Watanabe T, Suzuki A, Ohmori T, Tsuchiya M, Suzuki T, Ohta H, Murakami N, Itoh Y.

Diagn Microbiol Infect Dis. 2014 May;79(1):93-7. doi: 10.1016/j.diagmicrobio.2014.01.012.

PMID:
24565849
2.

Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients.

Hirano R, Sakamoto Y, Tachibana N, Ohnishi M.

Int J Clin Pharm. 2014 Aug;36(4):795-9. doi: 10.1007/s11096-014-9961-6.

PMID:
24913359
3.

Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy.

Niwa T, Suzuki A, Sakakibara S, Kasahara S, Yasuda M, Fukao A, Matsuura K, Goto C, Murakami N, Itoh Y.

Clin Ther. 2009 Oct;31(10):2126-33. doi: 10.1016/j.clinthera.2009.10.017.

PMID:
19922883
4.

Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy.

Takahashi Y, Takesue Y, Nakajima K, Ichiki K, Tsuchida T, Tatsumi S, Ishihara M, Ikeuchi H, Uchino M.

J Infect Chemother. 2011 Jun;17(3):382-7. doi: 10.1007/s10156-010-0182-1.

PMID:
21127934
5.

Immediate hematological toxicity of linezolid in healthy volunteers with different body weight: a phase I clinical trial.

Cai Y, Chai D, Falagas ME, Vouloumanou EK, Wang R, Guo D, Bai N, Liang B, Liu Y.

J Antibiot (Tokyo). 2012 Apr;65(4):175-8. doi: 10.1038/ja.2011.142.

PMID:
22274702
6.

Risk factors for linezolid-associated thrombocytopenia in adult patients.

Natsumoto B, Yokota K, Omata F, Furukawa K.

Infection. 2014 Dec;42(6):1007-12. doi: 10.1007/s15010-014-0674-5.

7.

Thrombocytopenia associated with linezolid therapy.

Attassi K, Hershberger E, Alam R, Zervos MJ.

Clin Infect Dis. 2002 Mar 1;34(5):695-8.

8.

High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease.

Wu VC, Wang YT, Wang CY, Tsai IJ, Wu KD, Hwang JJ, Hsueh PR.

Clin Infect Dis. 2006 Jan 1;42(1):66-72.

9.

Linezolid-associated thrombocytopenia.

Lam S.

Consult Pharm. 2012 Jul;27(7):504-8. doi: 10.4140/TCP.n.2012.504.

PMID:
22910131
10.

Efficacy and safety of linezolid in liver transplant patients.

Radunz S, Juntermanns B, Kaiser GM, Treckmann J, Mathe Z, Paul A, Saner FH.

Transpl Infect Dis. 2011 Aug;13(4):353-8. doi: 10.1111/j.1399-3062.2011.00617.x.

PMID:
21355969
11.

Influence of linezolid clearance on the induction of thrombocytopenia and reduction of hemoglobin.

Hiraki Y, Tsuji Y, Matsumoto K, Morita K, Kamimura H, Karube Y.

Am J Med Sci. 2011 Dec;342(6):456-60. doi: 10.1097/MAJ.0b013e318218cf18.

PMID:
21681075
12.

Linezolid: low pre-treatment platelet values could increase the risk of thrombocytopenia.

Grau S, Morales-Molina JA, Mateu-de Antonio J, Marín-Casino M, Alvarez-Lerma F.

J Antimicrob Chemother. 2005 Aug;56(2):440-1. No abstract available.

13.

Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid.

Soriano A, Ortega M, García S, Peñarroja G, Bové A, Marcos M, Martínez JC, Martínez JA, Mensa J.

Antimicrob Agents Chemother. 2007 Jul;51(7):2559-63.

14.

Linezolid-induced thrombocytopenia in impaired renal function: is it time for a dose adjustment? A case report and review of literature.

Cossu AP, Musu M, Mura P, De Giudici LM, Finco G.

Eur J Clin Pharmacol. 2014 Jan;70(1):23-8. Review.

PMID:
24022332
15.

A comparative evaluation of adverse platelet outcomes among Veterans' Affairs patients receiving linezolid or vancomycin.

Patel N, VanDeWall H, Tristani L, Rivera A, Woo B, Dihmess A, Li HK, Smith R, Lodise TP.

J Antimicrob Chemother. 2012 Mar;67(3):727-35. doi: 10.1093/jac/dkr522.

16.

Probable linezolid-induced thrombocytopenia in a patient with vancomycin-resistant enterococci.

Poulakos MN, Grace Y, Coakley C.

J Pharm Pract. 2012 Dec;25(6):615-8. doi: 10.1177/0897190012442720.

PMID:
22544622
17.

Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant Staphylococcus aureus-infected patients after digestive surgery.

Ikuta S, Tanimura K, Yasui C, Aihara T, Yoshie H, Iida H, Beppu N, Kurimoto A, Yanagi H, Mitsunobu M, Yamanaka N.

J Infect Chemother. 2011 Jun;17(3):388-91. doi: 10.1007/s10156-010-0188-8.

PMID:
21161560
18.

Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction.

Tsuji Y, Hiraki Y, Matsumoto K, Mizoguchi A, Kobayashi T, Sadoh S, Morita K, Kamimura H, Karube Y.

J Infect Chemother. 2011 Feb;17(1):70-5. doi: 10.1007/s10156-010-0080-6.

PMID:
20582446
19.

Linezolid-related immune-mediated severe thrombocytopenia.

Pascoalinho D, Vilas MJ, Coelho L, Moreira P.

Int J Antimicrob Agents. 2011 Jan;37(1):88-9. doi: 10.1016/j.ijantimicag.2010.10.001. No abstract available.

PMID:
21075603
20.

Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients.

Matsumoto K, Shigemi A, Takeshita A, Watanabe E, Yokoyama Y, Ikawa K, Morikawa N, Takeda Y.

Int J Antimicrob Agents. 2014 Sep;44(3):242-7. doi: 10.1016/j.ijantimicag.2014.05.010.

PMID:
25108880
Items per page

Supplemental Content

Support Center